$4.49
Alector is a biotechnology business based in the US. Alector shares (ALEC) are listed on the NASDAQ and all prices are listed in US Dollars. Alector employs 245 staff and has a trailing 12-month revenue of around $55.3 million.
Our top picks for where to buy Alector stock
How to buy Alector stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ALEC. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Alector stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Alector stock price (NASDAQ: ALEC)
Use our graph to track the performance of ALEC stocks over time.Alector shares at a glance
Latest market close | $4.72 |
---|---|
52-week range | $3.66 - $8.90 |
50-day moving average | $5.28 |
200-day moving average | $5.80 |
Wall St. target price | $13.75 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-1.81 |
Is it a good time to buy Alector stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Alector price performance over time
Historical closes compared with the close of $4.72 from 2024-09-03
1 week (2024-08-29) | -9.58% |
---|---|
1 month (2024-08-05) | -6.72% |
3 months (2024-06-05) | -1.67% |
6 months (2024-03-05) | -29.92% |
1 year (2023-09-05) | -9.14% |
---|---|
2 years (2022-09-02) | -54.88% |
3 years (2021-09-03) | 26.64 |
5 years (2019-09-05) | 16.6 |
Alector financials
Revenue TTM | $55.3 million |
---|---|
Gross profit TTM | $-76,801,000 |
Return on assets TTM | -18.3% |
Return on equity TTM | -92.64% |
Profit margin | -290.66% |
Book value | $1.55 |
Market Capitalization | $513.9 million |
TTM: trailing 12 months
Alector share dividends
We're not expecting Alector to pay a dividend over the next 12 months.
Alector share price volatility
Over the last 12 months, Alector's shares have ranged in value from as little as $3.66 up to $8.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alector's is 0.723. This would suggest that Alector's shares are less volatile than average (for this exchange).
Alector overview
Alector, Inc. , a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Frequently asked questions
nullWhat percentage of Alector is owned by insiders or institutions?
Currently 8.776% of Alector shares are held by insiders and 86.099% by institutions. How many people work for Alector?
Latest data suggests 245 work at Alector. When does the fiscal year end for Alector?
Alector's fiscal year ends in December. Where is Alector based?
Alector's address is: 131 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 What is Alector's ISIN number?
Alector's international securities identification number is: US0144421072 What is Alector's CUSIP number?
Alector's Committee on Uniform Securities Identification Procedures number is: 014442107
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
6 stocks like Nvidia you need to consider
Advanced Micro Devices (AMD), Intel Corporation (INTC) and Qualcomm Inc (QCOM) are top stocks like Nvidia. See our full list here.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question